Barclays PLC Lyell Immunopharma, Inc. Transaction History

Barclays PLC

$377 Billion
Q3 2024

A detailed history of Barclays PLC transactions in Lyell Immunopharma, Inc. stock. As of the latest transaction made, Barclays PLC holds 240,615 shares of LYEL stock, worth $146,775. This represents 0.0% of its overall portfolio holdings.

Number of Shares

240,615

Previous 240,615 -0.0%

Holding current value

$146,775

Previous $332,000 -0.0%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 15, 2024	BUY	$1.13 - $1.88 $206,015 - $342,752	182,315 Added 312.72%	240,615 $332,000
Q2 2024 Aug 14, 2024	SELL	$1.3 - $3.01 $114,713 - $265,605	-88,241 Reduced 60.22%	58,300 $84,000
Q1 2024 May 15, 2024	SELL	$1.71 - $3.07 $199,264 - $357,744	-116,529 Reduced 44.3%	146,541 $326,000
Q4 2023 Feb 15, 2024	BUY	$1.39 - $2.35 $24,779 - $41,893	17,827 Added 7.27%	263,070 $510,000
Q3 2023 Nov 07, 2023	BUY	$1.45 - $3.35 $68,113 - $157,366	46,975 Added 23.69%	245,243 $362,000
Q2 2023 Aug 03, 2023	SELL	$1.89 - $3.86 $88,797 - $181,354	-46,983 Reduced 19.16%	198,268 $630,000
Q1 2023 May 04, 2023	SELL	$1.97 - $3.58 $177,609 - $322,762	-90,157 Reduced 26.88%	245,251 $579,000
Q4 2022 Feb 13, 2023	BUY	$2.78 - $8.09 $557,946 - $1.62 Million	200,700 Added 148.99%	335,408 $1.16 Million
Q3 2022 Nov 03, 2022	BUY	$5.54 - $8.27 $698,172 - $1.04 Million	126,024 Added 1451.22%	134,708 $988,000
Q2 2022 Aug 12, 2022	SELL	$3.68 - $6.8 $88,154 - $162,894	-23,955 Reduced 73.39%	8,684 $57,000
Q1 2022 May 16, 2022	BUY	$5.05 - $7.7 $164,826 - $251,320	32,639 New	32,639 $164,000

Others Institutions Holding LYEL

# of Institutions

121

Shares Held

142M

Call Options Held

18.1K

Put Options Held

200

View Full List

About Lyell Immunopharma, Inc.

Ticker LYEL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 247,824,992
Market Cap $151M
Description
Lyell Immunopharma, Inc., a T cell reprogramming company, engages in developing T cell therapies for patients with solid tumors. The company develops therapies using technology platforms, such as Gen-R, an ex vivo genetic reprogramming technology to overcome T cell exhaustion; and Epi-R, an ex vivo epigenetic reprogramming technology to generate...

More about LYEL

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

News

Stay updated on Barclays PLC with notifications on news.

Account